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Chronic respiratory diseases (CRDs) are major non-communicable diseases (NCDs) [1, 2] that induce a 
significant burden. Asthma often occurs along the life cycle from early childhood, affecting 30 million children 
and adults under 45 years of age in Europe [3]. Chronic obstructive pulmonary disease (COPD) has an estimated 
annual death rate of over 3 million people globally [1, 2]. The annual direct and indirect costs in the 28 European 
Union (EU) countries due to COPD or asthma are estimated at 48 billion euros and 34 billion euros respectively 
[3]. Rhinitis occurs in over 100 million people in Europe, and indirect costs are enormous [4]. Asthma is a 
common risk factor for COPD [5, 6]. CRDs impact ageing and should be prevented, recognised and managed 
across the life cycle to promote active and healthy ageing (AHA). There is an urgent need to act globally. 
European Innovation Partnerships (EIPs) aim to enhance EU competitiveness and tackle societal challenges 
through research and innovation. To tackle the potential of ageing in the EU, the European Commission, within 
its Innovation Union policy, launched the EIP on AHA (between the Directorate General for Health and Food 
Safety (DG Santé) and Directorate General for Communications Networks, Content and Technology (DG 
CONNECT)) [7]. The B3 Action Plan promotes integrated care models for chronic diseases, including the use of 
remote monitoring. 
The initiative AIRWAYS-ICPs (integrated care pathways for airway diseases) [8] has been approved by the EIP 
on AHA as the model of chronic diseases of the B3 Action Plan. It is a Research Demonstration Project of the 
World Health Organization's Global Alliance against Chronic Respiratory Diseases (GARD) [1]. AIRWAYS-
ICPs was initiated in 2013 by the WHO Collaborating Centre of Montpellier and the EIP on AHA Reference Site 
MACVIA-LR (Contre les MAladies Chroniques Pour un VIeillissement Actif en Languedoc-Roussillon, France) 
led by the Region Languedoc-Roussillon (France) [9]. 
The GARD action plan was the model of AIRWAYS-ICPs (figure 1). 
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Objectives 
The aim of AIRWAYS-ICPs is to launch a collaboration to develop practical multisectoral care pathways (ICPs) 
to reduce the burden of chronic respiratory diseases, their mortality and multimorbidity. AIRWAYS-ICPs 
proposes a feasible, achievable and manageable project from science to guidelines and policies using existing 
networks and stakeholders committed to the Action Plan B3 of the EIP on AHA and GARD [1, 2]. It is 
implemented in European countries and regions, as part of the EIP on AHA, and is scaled up globally with 
GARD. 
 
FIGURE 1 AIRWAYS-ICPs (integrated care pathways for airway diseases] interactions between the European 
Union and World Health Organization. NGO: nongovernmental organisation; GO: governmental organisation, 
MOH: Ministry of Health; GARD: Global Alliance against Chronic Respiratory Diseases; NCD: non-
communicable disease; EIP: European Innovation Partnership; AHA: active and healthy ageing; DG Sante: 
Directorate General for Health and Food Safety; DG CONNECT: Directorate General for Communications 
Networks, Content and Technology; MeDALL WP10: Mechanisms of the Development of Allergy workpackage 




AIRWAYS-ICPs activities are being implemented by a group of 450 members in 70 countries. Members also 
include those of previous initiatives such as ARIA (Allergic Rhinitis and its Impact on Asthma; initiated in 
collaboration with WHO) [10] and GARD [1, 2]. The majority of members have been working together since 
1999. The GA
2
LEN (Global Allergy and Asthma European Network, Sixth Framework Programme) network of 
excellence centres of allergy and asthma [11] and members of EIP on AHA commitments for action are also 
involved. All stakeholders needed for the implementation of an action plan at the national and local levels 
actively participate. Scientific societies also participate in the project. 
Implementation of the AIRWAYS-ICPs action plan 
The action plan was devised by a group of 450 members and implemented in 2013 [8]. Activities are proposed in 
a logical framework from existing tools to novel information communication technology (ICT) tools and 
innovative health systems in order to provide an integrated solution for CRDs across the life cycle. The model of 
CRD can then be used for the health promotion of AHA and management of CRDs in older adults. 
 Proposing a common framework of care pathways (ICPs) for CRDs to facilitate comparability and 
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trans-national initiatives targeted to all populations according to culture, health systems and income 
[12]: AIRWAYS-ICPs is participating in the development of a repository that is currently being 
developed by the EU and that will be available in December 2015. This repository will include good 
practices in CRDs such as National Institute for Health and Care Excellence (NICE; UK) guidance, 
national programmes for CRDs [13], asthma, COPD or allergy [14-16], guidelines for asthma, COPD or 
allergic rhinitis [10, 17-20], and ICPs. 
 Developing a strategy for low-resource settings based on existing WHO initiatives such as the WHO 
Package of Essential Noncommunicable disease [21] and the essential list of drugs, as well as validated 
primary management strategies in low- and middle-income countries [22]. 
 Aiding risk stratification in chronic disease patients with a common strategy. AIRWAYS-ICPs has 
developed a simple stratification algorithm for asthma control and severity (following a 2009 WHO 
meeting) which can be extended to all chronic diseases unifying the classification of the diseases for 
clinical, research and public health use [23-25], 
 Defining important questions on CRDs in older adults. There are no specific recommendations for 
CRDs in older adults and a research activity is ongoing to better understand asthma, COPD and their 
multimorbidities in old age. 
 Developing multisectoral care pathways for CRDs and their multimorbidities across the life cycle, 
implementing emerging technologies for individualised and predictive medicine. Within the past four 
decades, an epidemic of allergic diseases and asthma has been observed globally in children and adults. 
The expected epidemic wave of asthma and rhinitis in older adults is an insufficiently recognised 
problem. In Europe, over 20% of adults suffer from allergic rhinitis and over 5% from asthma. These 
patients are now reaching the age of 65 years and a new health problem in old age people will be to 
understand, detect and manage these patients who also suffer from NCD multimorbididy and 
polymedication. There is an urgent need for a simple tool which would allow individualised and 
predictive medicine. AIRWAYS-ICPs is tackling this expected health problem, based on systems 
medical principles, in accordance with guidelines proposed by the European Commission (www.casym. 
eu) using the MACVIA-ARIA Sentinel NetworK (MASK). A common language is being used at the 
patient, pharmacist and physician levels using tablets and cell phones (figure 2). 
 A first project directly linked with the activities of the WHO Collaborating Centre on rhinitis and 
asthma was initiated in 2013 and has been completed [10, 26-30]. MASK proposes the study of 
symptoms of patients suffering from allergic symptoms during the pollen season (rhinitis and asthma) in 
order to make them sentinels for the onset and severity of the pollen season. Patients are geolocalised 
and evaluate their symptoms by visual analogue scale using a cell phone with a touch screen or internet. 
A clinical decision support system will be finalised in December 2015. A care pathway from the patient 
to health care professionals has been built (figure 2) and a clinical decision support system will be 
available in December 2015. 
 The system has been extended to persistent rhinitis and asthma, and a pulmonary function test using cell 
phones is currently being tested (available mid 2016). This may be of interest in all countries to screen 
for bronchial obstruction (asthma and COPD) by patients or at primary healthcare centres. 
 The application is available in 15 languages from the App store (iOS) and Google play (Android). It is 
free for patients and, due to the simplicity of the tool, it can be used in developed and many developing 
countries (if a smart phone is available). 
 Embedding the concept of frailty into CRDs and proposing an operational AHA questionnaire 
developed by the Reference Site Network of the EIP on AHA using WHO Disability Assessment 
Schedule 2.0 and quality-of-life questionnaires [31, 32]. Unrecognised CRDs can be detected in frail 
elderly patients [33]. Optimising treatment and integrated care services of frail COPD patients with 
multimorbidities and polypharmacy improves certain health outcomes [34], 
 Scaling up strategies in Europe and beyond. The scaling up strategy has been clearly defined and 
approved by AIRWAYS-ICPs members. It follows the EIP-AHA recommendations on a five-step 
framework: 1) what to scale up: 1-1) databases of good practices; 1-2) assessment of viability of the 
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scaling up of good practices; 1-3) classification of good practices for local replication; and 2) how to 
scale up: 2-1) facilitating partnerships for scaling up; 2-2) implementation of key success factors and 
lessons learnt, including emerging technologies for individualised and predictive medicine. Scaling up 
will take place within and beyond Europe with GARD [35-40], • Strengthening the WHO NCD Action 
Plan. AIRWAYS-ICPs is in line with the WHO NCD Action Plan since it aims to reduce the 
preventable and avoidable burden of morbidity, mortality and disability by means of multisectoral 
collaboration and cooperation at national, regional and global levels. 
 
FIGURE 2 Care pathways for rhinitis and asthma multimorbidity across the life cycle. OTC: over-the-counter. 




AIRWAYS-ICPs is expected in the short term to reduce morbidity, and improve education and work and in the 
long term to promote AHA [41]. AIRWAYS-ICPs has strategic relevance to the EU Health Strategy and the 
WHO NCD Action Plan (2013-2020), adding value to existing public health knowledge. 
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